(lp0
S'United Therapeutics Reaches Analyst Target Price Nasdaq - 16 hours ago In recent trading, shares of United Therapeutics Corp  have crossed above the average analyst 12-month target price of $140.80, changing hands for $142.08/share.Top Institutional Investors That Own United Therapeutics Corporation  - Post AnalystUnited Therapeutics Co.  Given Underperform Rating at Jefferies Group LLC - The Cerbat Gem'
p1
aS'Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation Motley Fool - Feb 22, 2017 Pitting Organovo Holdings  against United Therapeutics  might seem a bit strange. Organovo is much smaller than United Therapeutics. Their products have little in common. However, both of these healthcare stocks have&nbsp;...United Therapeutics  Q4 2016 Results - Earnings Call Transcript - Seeking Alpha'
p2
aS'Credit Suisse Starts United Therapeutics Corp.  at Underperform StreetInsider.com - Mar 16, 2017 Credit Suisse initiates coverage on United Therapeutics Corp.  with a Underperform rating and a price target of $120.00.United Therapeutics Corporation  Moves Lower on Volume Spike for March 16 - Equities.comAnalyst Activity  Credit Suisse Group AG Initiates Coverage On United ... - Market Exclusive'
p3
aS'United Therapeutics Corporation To Present At Barclays Global Healthcare ... PR Newswire  - Mar 7, 2017 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 7, 2017 /PRNewswire/ -- United Therapeutics Corporation  announced today that Martine Rothblatt, Ph.UPDATE: Jefferies Downgrades United Therapeutics Corp.  to Underperform - StreetInsider.comUnited Therapeutics Corp  Files Form 4 Insider Selling : Martine A ... - Energy Index'
p4
aS'United Therapeutics feels squeeze from increased pulmonary hypertension ... Washington Business Journal - Feb 23, 2017 United Therapeutics Corp.  blames increasing competition in the pulmonary arterial hypertension space for its lower-than-expected revenue last year, CEO Martine Rothblatt told analysts Wednesday.'
p5
aS'Risk Malaise Alert in Option Market: United Therapeutics Corporation Implied ... CML News - 11 hours ago Before we dive into any analysis we simply note that United Therapeutics Corporation  risk is actually priced pretty low by the option market as of right now.'
p6
aS'Credit Suisse negative on United Therapeutics; shares slip 4% Seeking Alpha - Mar 16, 2017 United Therapeutics  goes south on modestly higher volume on the heels of an Underperform rating and $120  price target by Credit Suisse.'
p7
aS"Northwell Health and United Therapeutics Announce Strategic Partnership to ... PR Newswire  - Mar 9, 2017 MANHASSET, N.Y. and SILVER SPRING, Md., March 9, 2017 /PRNewswire/ -- Northwell Health's Feinstein Institute for Medical Research and United Therapeutics Corporation  announced today a strategic partnership focused on the&nbsp;...Northwell, drug-maker ink bioelectronics partnership - Innovate Long Island"
p8
aS'How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United ... Yahoo Finance - 18 hours ago For today, Stock-Callers.com draws attention to select Drug Manufacturers stocks, namely: Orexigen Therapeutics Inc. , United Therapeutics Corp. , DURECT Corp. , and SciClone Pharmaceuticals Inc. . These companies are&nbsp;...'
p9
aS"United Therapeutics Corporation To Present At Cowen And Company 37th Annual ... PR Newswire  - Feb 28, 2017 28, 2017 /PRNewswire/ -- United Therapeutics Corporation  announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the&nbsp;..."
p10
a.